Daewoong Pharma 
Welcome,         Profile    Billing    Logout  
 47 Products   37 Diseases  47 Products   122 Trials   1590 News 
156 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Acelex (polmacoxib) / CG Invites
NCT06590714: Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.

Recruiting
N/A
150
RoW
Experimental(Acelex cap m2mg), Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)
Eulji University Hospital, Dong-A ST Co., Ltd., Seoul National University Hospital
Rotator Cuff Tear
08/25
08/25
Olostar (rosuvastatin/olmesartan medoxomil) / Daewoong Pharma, Daiichi Sankyo
NCT05411887: Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

Active, not recruiting
N/A
2845
RoW
Rosuvastatin, Olmesartan Medoxomil
Daewoong Pharmaceutical Co. LTD.
Hyperlipidemias, Hypertension
03/25
06/25
Jeuveau (prabotulinumtoxinA-xvfs) / AEON Biopharma
NCT05840445: Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles

Completed
4
26
RoW
Onabotulinum toxin A, Botox, Prabotulinumtoxin A, Nabota
Instituto de Oftalmología Fundación Conde de Valenciana
Face, Skin Fold, Rejuvenation
01/21
01/21
NCT06903975: BoTox Into the Sternocleidomastoid Muscles (SCM)

Recruiting
4
30
US
prabotulinumtoxinA-xvfs, Jeuveau
Boston Medical Center, Evolus, Inc.
Neck Muscle Issue
03/26
03/26
NCT06354127: DWP450 for Treating Moderate to Severe Glabellar Lines

Completed
3
473
RoW
DWP450, Botox®
Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
11/20
01/21
EVOLUS-CLIN201, NCT05320393: Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Completed
2
154
US
PrabotulinumtoxinA-Xvfs, Jeuveau, OnabotulinumtoxinA, Botox Cosmetic
Evolus, Inc., ethica Clinical Research Inc.
Glabellar Frown Lines
05/23
05/23
NCT04871451: Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia

Completed
2
51
US
ABP-450, prabotulinumtoxinA
AEON Biopharma, Inc., PPD
Cervical Dystonia
07/23
07/23
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT04965311: Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Terminated
2
4
US
Botulinum Toxin Type A, AbobotulinumtoxinA, Botox, Botox Cosmetic, Botulinum A Toxin, Botulinum Neurotoxin Type A, Botulinum Toxin A, BTX-A, DaxibotulinumtoxinA, Dysport, EvabotulinumtoxinA, IncobotulinumtoxinA, OnabotulinumtoxinA, Onaclostox, Prabotulinumtoxin A, Xeomin
OHSU Knight Cancer Institute, Oregon Health and Science University
Pancreatic Carcinoma
07/24
07/24
NCT05016661: Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

Terminated
2
466
Canada, US, RoW
ABP-450, prabotulinumtoxinA
AEON Biopharma, Inc., PPD DEVELOPMENT, LP
Migraine
07/24
08/24
NCT04715048: Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Active, not recruiting
1
20
US
PrabotulinumtoxinA, Jeuveau, Onabotulinum toxin A, Botox
University of Southern California
Glabellar Frown Lines
05/25
06/25
NCT05129319: Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Completed
1
30
US
prabotulinumtoxinA, Jeuveau
Clinical Testing of Beverly Hills, Evolus, Inc.
Glabellar Frown Lines
06/23
06/23
NCT05807412: Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Completed
1
10
US
PrabotulinumtoxinA-Xvfs, Jeaveau, OnabotulinumtoxinA, Botox
Lupo Center for Aesthetic and General Dermatology, Evolus, Inc.
Rhytides
02/24
02/24
NCT06604832: Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Recruiting
1
20
US
PrabotulinumtoxinA-Xvfs, Jeuveau, IncobotulinumtoxinA, Xeomin, saline solution (placebo)
Kalpna Kay Durairaj, MD, FACS, Evolus, Inc.
Skin Aging, Skin Wrinkling
01/25
02/25
NCT05889026: The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity

Completed
N/A
16
RoW
Extracorporeal shock wave therapy, Botulinum toxin treatment
Korea University Guro Hospital, Daewoong Pharmaceutical Co. LTD.
Stroke, Hemiplegia, Spastic, Muscle Spasticity
09/21
09/21
JBDX, NCT05167864: Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Completed
N/A
143
US
Onabotulinumtoxina for Injection, Botox, Abobotulinumtoxina for Injection, Dysport, IncobotulinumtoxinA for Injection, Xeomin, PrabotulinumtoxinA for Injection, Jeuveau
University of Pennsylvania
Cosmetic Techniques
06/23
06/23
NCT05481931: Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Recruiting
N/A
750
Europe
prabotulinumtoxinA, Jeuveau, Nuceiva
Evolus, Inc., Avania
Glabellar Frown Lines
12/25
01/26
Novosis (bongros/BMP-2) / Daewoong Pharma
2008-000926-38: An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 3.57 mg implant versus the reference product Enantone Monats-Depot

Ongoing
3
40
Europe
Novosis Leuprorelin 3.57 Implant, Implant, Enantone(R) Monats-Depot
Novosis AG
Patients who have advanced carcinoma of the prostate suitable for hormonal manipulation
 
 
NCT07017634: Efficacy and Safety of NOVOSIS Putty for Interbody Lumbar Fusion Cases

Not yet recruiting
3
316
NA
Novosis Putty, Standard of Care
CGBio Inc., CGBio USA
Degenerative Disc Disease
01/28
01/31
NCT06715345: Efficacy and Safety of Novosis Putty for Degenerative Lumbar Disease

Active, not recruiting
N/A
48
RoW
Bone graft materials and rhBMP-2
CGBio Inc.
Degenerative Lumbar Diseases
06/24
12/25
tanfanercept (HL036) / Daewoong Pharma
ChiCTR2000039903: A Phase 3, Multicenter, Randomized, Double–Blinded and Placebo–Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects with Moderate and Severe Dry Eye

Recruiting
3
674
 
Local administration of HBM9036 (HL036) eye drops (0.25%) to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks ;Local administration of placebo to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks
Xiamen Eye Center Affiliated to Xiamen University; Harbour BioMed (Guangzhou) Co., Ltd., Fully self-funded
Dry Eye
 
 
NCT04633213: A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Recruiting
3
674
RoW
HBM9036 0.25% Ophthalmic Solution, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye
12/22
04/23
VELOS-4, NCT06400589: A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Suspended
3
750
US
tanfanercept, Vehicle
HanAll BioPharma Co., Ltd.
Dry Eye
08/25
08/25
batoclimab (IMVT-1401) / Roivant
2021-000249-42: Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG Studio di fase 3 per valutare l’efficacia e la sicurezza di Batoclimab come terapia di induzione e di mantenimento in partecipanti adulti affetti da miastenia grave generalizzata (gMG).

Ongoing
3
240
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Diseases [C] - Nervous System Diseases [C10]
 
 
MG, NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized Patients

Completed
3
132
RoW
HBM9161 Injection (680mg), Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
01/23
01/23
2022-002787-68: Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Studio di fase 3 per testare Batoclimab in partecipanti affetti da oftalmopatia tiroidea (TED) attiva

Not yet recruiting
3
100
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences, GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Diseases [C] - Eye Diseases [C11]
 
 
NCT05332210: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Recruiting
3
144
RoW
HBM9161 Injection (680mg)
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
09/23
12/23
ChiCTR2100050903: Multicenter, randomized, double-blind, placebo-controlled, phase 2/3 operational seamless, group sequential design study of the efficacy and safety of HBM9161 subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia Gravis
 
 
NCT05403541 / 2021-000249-42: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Active, not recruiting
3
240
Europe, Canada, Japan, US, RoW
Batoclimab 680 mg SC weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis
03/25
04/25
ChiCTR2200059452: A long-term open-label extension study to evaluate the safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 680 mg was administered once a week (QW) ;HBM9161 340mg was administered 6 times per cycle for two cycles
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia gravis
 
 
NCT05517421 / 2022-002787-68: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Active, not recruiting
3
100
Europe, Canada, Japan, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05524571 / 2022-002788-30: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Recruiting
3
100
Europe, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05517447 / 2022-002839-66: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Recruiting
3
180
Europe, US, RoW
Observational cohort study, Batoclimab, IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
08/26
08/26
NCT04428255: A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Recruiting
2/3
36
RoW
HBM9161 Dose A, HBM9161 Dose B, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Primary Immune Thrombocytopenic Purpura
07/21
03/23
NCT05015127: A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Recruiting
2/3
36
RoW
HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7
Harbour BioMed (Guangzhou) Co. Ltd.
Thyroid Ophthalmopathy
10/22
12/22
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients, ChiCTR2000033560: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
HBM9161 dose 1 ;HBM9161 dose 2 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Myasthenia Gravis
 
 
ChiCTR2100050401: A randomized, double-blind, placebo-controlled, phase 2/3 operational seamless design clinical study to evaluate the efficacy and safety of subcutaneous injection of HBM9161 in Chinese patients with active, moderate-to-severe thyroid eye disease (TED)

Not yet recruiting
2
30
 
HBM9161 Once a week ;HBM9161 1 time / week + 2 times / week ;Placebo
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Harbour BioMed(Suzhou) Co., Ltd., Harbour BioMed(Suzhou) Co., Ltd.
Thyroid Eye Disease (TED)
 
 
2022-002894-27: Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones.

Not yet recruiting
2
45
Europe
batoclimab, IMVT-1401, Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves, disease, An immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism)., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05907668 / 2022-002894-27: A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Active, not recruiting
2
35
Europe
IMVT-1401 (batoclimab), IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves Disease
07/25
07/25
NCT05581199 / 2022-002718-17: To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Active, not recruiting
2
277
Europe, Canada, US, RoW
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Placebo
Immunovant Sciences GmbH, Immunovant Sciences, GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
01/26
01/27
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China.

Recruiting
1
18
 
HBM9161
The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Neuromyelitis optica spectrum disorders
 
 
Eligard (leuprolide acetate) / Tolmar, Sanofi
2006-001909-28: Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de la recidiva bioquímica del cáncer de próstata tratado con radioterapia.

Ongoing
4
180
Europe
BUSERELINA, GOSERELINA, LEUPRORELINA, TRIPTORELINA, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL
Grupo GICOR
Cáncer de próstata tratado con radioterapia y que presenta recidiva bioquímica.
 
 
2011-004749-41: The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatment

Ongoing
4
400
Europe
Casodex 50mg, Eligard 22.5 mg, N/A, Casodex 50mg, Eligard 22.5 mg, Casodex 50mg, Eligard 22.5 mg
TweeSteden hospital, Astella's pharma
Localized prostate cancer
 
 
NEST, NCT06926933: Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

Recruiting
4
50
RoW
Eligard® 45 mg
HanAll BioPharma Co., Ltd.
CPP
04/26
10/27
NCT02811471: Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Recruiting
3
5
US
Leuprolide
Nemours Children's Clinic, Tolmar Inc.
Central Precocious Puberty
07/17
07/18
2019-003177-26: Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Vergelijken van gerichte radiotherapie met en zonder kortdurende hormonale behandeling (6 maanden)

Not yet recruiting
3
280
Europe
Eligard, Powder for suspension for injection, Eligard, Leuproline acetaat 1x 45 mg sc
UMCG, UMCG
Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases Patiënten met biochemisch recidief na primaire behandeling van prostaatkanker met ≤4 metastasen, Metastatic prostate cancer Uitgezaaide prostaat kanker, Diseases [C] - Cancer [C04]
 
 
2022-000066-18: Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen. Onderzoek naar metastase gerichte therapie al dan niet in combinatie met hormoontherapie bij patiënten met een herval van prostaatkanker na initiële behandeling en maximum 5 metastasen.

Not yet recruiting
3
873
Europe
Implant in pre-filled syringe, Powder and solvent for solution for injection, Powder and solvent for suspension for injection, Capsule, soft, Zoladex 3,6 mg implant, Depo-Eligard 7,5 mg implant, Decapeptyl Sustained Release 11,25 mg, Zoladex Long Acting, 10,8 mg, implantaat, Depo-Eligard 45 mg implant, Depo-Eligard 22,5 mg implant, Decapeptyl Sustained Release 3,75 mg, Decapeptyl Sustained Release 22,5 mg, Xtandi 40 mg soft capsules
Universitaire Ziekenhuizen Leuven, Universitaire Ziekenhuizen Leuven
Oligorecurrent hormone-sensitive prostate cancer patients, Recurrent hormone-sensitive prostate cancer patients with maximum 5 metastasis, Diseases [C] - Cancer [C04]
 
 
2021-006975-41: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: un ensayo fase III aleatorizado, controlado, multicéntrico

Not yet recruiting
3
534
Europe
triptorelina equivalente, triptorelina (pamoato), leuprorelina, goserelina, Powder and solvent for prolonged-release suspension for injection, Powder and solvent for solution for injection, Powder and solution for solution for injection, Powder and solvent for suspension for injection in pre-filled syringe, Powder and solvent for solution for injection in pre-filled syringe, Implant in pre-filled syringe, Decapeptyl semestral, Decapeptyl trimestral, Eligard mensual, Eligard semestral, Eligard trimestral, Procrin Mensual, Procrin Semestral, Procrin Trimestral, Zoladex
GICOR, GICOR
Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía, prostate cancer cáncer de próstata, Diseases [C] - Cancer [C04]
 
 
ADOPT, NCT04302454: Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

Active, not recruiting
3
280
Europe
Radiotherapy, MDRT, Metastase-directed radiotherapy, SBRT, Stereotactic body radiotherapy, Leuprorelin, Eligard
University Medical Center Groningen, Dutch Cancer Society
Prostate Cancer
10/27
12/27
EMBARK, NCT02319837 / 2014-001634-28: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer

Active, not recruiting
3
1068
Europe, Canada, US, RoW
Enzalutamide, MDV3100, Xtandi, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label, Eligard, Leuprolide Acetate, Leuprorelin, Lupron
Pfizer, Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
01/23
09/26
PCS-XII, NCT06855589: Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

Not yet recruiting
3
400
Canada
6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
Charles LeMoyne Hospital
Prostate Cancer (Adenocarcinoma)
03/33
03/34
OVELIA, NCT04906395: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Active, not recruiting
3
250
Canada, US, RoW
TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
Tolmar Inc.
Breast Cancer
04/26
04/26
AFU-GETUG-20, NCT01442246 / 2010-022037-29: Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Active, not recruiting
3
700
Europe
Leuprorelin Acetate, Eligard®
UNICANCER, Astellas Pharma Inc
Metastases
09/27
09/27
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
ERADICATE, NCT04484818: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The Study

Active, not recruiting
3
27
US
Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
12/25
05/28
NCT05645536: Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Enrolling by invitation
3
250
US, RoW
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Tolmar Inc.
Breast Cancer
06/28
06/28
INDICATE, NCT04423211: Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
3
804
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Degarelix, FE200486, Firmagon, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Proton Therapy, IMPT, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline, Volume Modulated Arc Therapy, VMAT, Volumetric Modulated Arc Therapy (procedure)
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
12/32
12/32
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
GROUQ-PCS 9, NCT02685397: Management of Castration-Resistant Prostate Cancer with Oligometastases

Active, not recruiting
2/3
102
Canada
Leuprolide Acetate, Eligard, Lupron, Goserelin Acetate, ZOLADEX, Triptorelin, Trelstar, Enzalutamide, Xtandi, Stereotactic Body Radiation Therapy, SBRT
Sir Mortimer B. Davis - Jewish General Hospital
Castration-resistant Prostate Cancer Patients with Oligometastases
04/27
08/41
NRG-GU002, NCT03070886: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Active, not recruiting
2/3
612
Canada, US
Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide, Leuprorelin, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908
NRG Oncology, National Cancer Institute (NCI)
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
05/26
05/26
ACTRN12609000108213: The utility of 18F-fluro-deoxy-glucose (FDG) and 11C-choline (C) positron emission tomography (PET scan) for radiotheraupetic management of high risk prostate cancer patients

Not yet recruiting
2
30
 
Austin Health, National Health and Medical Research Council (NHMRC)
Prostate cancer
 
 
NCT00544830: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting
2
29
US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
City of Hope Medical Center, National Cancer Institute (NCI)
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
03/11
03/26
OLIGOPELVIS, NCT02274779: Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Active, not recruiting
2
70
Europe
ELIGARD, Leuproréline
Institut Cancerologie de l'Ouest, Astellas Pharma Inc
Prostate Cancer
07/18
07/26
2022-002431-53: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER DAROLUTAMIDE (ODM-201) CONCOMITANT A LA RADIOTHERAPIE CHEZ LES PATIENTS PRESENTANT UN CANCER DE LA PROSTATE A RISQUE INTERMEDIAIRE DEFAVORABLE : UNE ETUDE MULTICENTRIQUE RANDOMISEE NON-COMPARATIVE DE PHASE II

Ongoing
2
62
Europe
DAROLUTAMIDE, Dégarélix, Goséréline, Leuproréline, Triptoréline, RADIOTHERAPY, Tablet, Powder and solvent for solution for injection, Implant in pre-filled syringe, , NUBEQA, FIRMAGON, ZOLADEX, ELIGARD, ENANTONE, DECAPEPTYL, GONAPEPTYL, RADIOTHERAPY
Institut Bergonié, Bayer Healthcare SAS
Prostate cancer Cancer de la prostate, Intermediate unfavorable risk prostate cancer Cancer de la prostate à risque intermédiaire défavorable, Diseases [C] - Cancer [C04]
 
 
2022-002571-11: EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer.

Ongoing
2
20
Europe
Powder and solution for solution for injection, Eligard 22.5mg
Institut Mutualiste Montsouris, Institut Mutualiste Montsouris
Intermediate risk localized prostate cancer Cancer localisé de la prostate à risque intermédiaire, Intermediate risk prostate cancer, Diseases [C] - Cancer [C04]
 
 
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
NCT02903368: Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Completed
2
118
US
Apalutamide, JNJ-56021927, ARN-509, Leuprolide, Lupron, Eligard, Prednisone, Deltasone, Abiraterone Acetate, Zytiga
Dana-Farber Cancer Institute, Janssen Scientific Affairs, LLC
Prostate Cancer
04/22
07/24
PROMPT, NCT04249154: Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Recruiting
2
77
Canada
Eligard, Radiation
McGill University Health Centre/Research Institute of the McGill University Health Centre, Tolmar Inc.
Prostate Cancer
12/26
12/27
NCT04734730: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting
2
70
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Talazoparib, BMN 673, BMN-673
City of Hope Medical Center, National Cancer Institute (NCI)
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
08/27
08/27
SHARP, NCT03361735: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting
2
25
US
Leuprolide Acetate, 377526, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate, 74381-53-6, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Goserelin Acetate, 606864, 65807-02-5, D-Ser(bu(t))(6)azgly(10)-LHRH Acetate, ZDX, Zoladex, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Radium Ra 223 Dichloride, 444811-40-9, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM CHLORIDE RA-223, Radium-223 Dichloride, Xofigo, Laboratory Biomarker Analysis, Degarelix, 214766-78-6, FE200486, Firmagon
City of Hope Medical Center
Prostate Adenocarcinoma
02/26
02/26
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
09/25
12/25
SATURN, NCT03902951: Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Active, not recruiting
2
28
US
Abiraterone Acetate, CB7630, Zytiga, Apalutamide, ARN 509, ARN-509, ARN509, JNJ 56021927, JNJ-56021927, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Jonsson Comprehensive Cancer Center, Janssen Inc.
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
01/26
01/27
NRG-GY033, NCT06169124: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Active, not recruiting
2
37
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Exemestane, Aromasin, FCE-24304, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI), NRG Oncology
Adult Ovarian Granulosa Cell Tumor
05/27
05/27
NCT06330805: Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Recruiting
2
70
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Contrast Agent, Contrast, Contrast Drugs, contrast material, Contrast Medium, Leuprolide, Leuprorelin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Physical Performance Testing, Physical Fitness Testing, Physical Function Testing, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385
Ohio State University Comprehensive Cancer Center, Pfizer, Myovant Sciences GmbH, Sumitomo Pharmaceuticals America
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
12/27
12/27
NCI-2018-01856, NCT01786265: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Active, not recruiting
2
310
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Flutamide, 4''-Nitro-3''-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
M.D. Anderson Cancer Center
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
02/27
02/27
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Recruiting
2
180
US
Placebo, Eligard 22.5Mg Suspension for Injection
Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
08/26
08/26
NCT07027124: Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Not yet recruiting
2
40
US
Darolutamide, Nubeqa, Pembrolizumab, Keytruda, Lupron, Leuprolide
Icahn School of Medicine at Mount Sinai, Merck Sharp & Dohme LLC, Bayer
Prostate Cancer, High-risk Prostate Cancer
12/26
05/31
RATIONAL-PCS, NCT06654336: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Not yet recruiting
2
162
Canada
Recurrence-directed therapy (RDT), ELIGARD 22.5mg
Ontario Clinical Oncology Group (OCOG), Ontario Clinical Oncology Group (OCOG) - McMaster University, TOLMAR PHARMACEUTIQUES CANADA, INC.
Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer
04/31
06/31
NCT06922318: The COSMYC Trial (COmbined Suppression of MYC)

Not yet recruiting
2
50
US
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex, Trelstar, Eligard, Lupron, Degarelix, Relugolix
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Zenith Epigenetics, National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
08/31
08/31
APEX, NCT06059118: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
50
US
DFMO, eflornithine, difluoromethylornithine, testosterone cypionate, DEPO-Testosterone Injection, Luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex, Trelstar, Eligard, Lupron, Degarelix, Relugolix, Enzalutamide, Xtandi
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Panbela Therapeutics, Prostate Cancer Foundation, United States Department of Defense
Prostate Cancer
01/26
11/29
NCT05669664: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recruiting
2
21
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
04/27
04/27
NCT05617885: Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Active, not recruiting
1/2
9
US
Darolutamide, Nubeqa, Abemaciclib, Verzenio, GNRH-A Leuprolide Acetate, Eligard, Lupron Depot, Lupron Depot-Ped, GNRH-A Goserelin, Zoladex, Degarelix, Firmagon
Praful Ravi, MB BCHir, MRCP, Eli Lilly and Company, Bayer
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
07/25
06/26
NCT06305598: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1
14
US
Biopsy, BIOPSY_TYPE, Bx, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Survey Administration, Testosterone Cypionate, depAndro, Depo-Testosterone, Depotest, Depovirin, Pertestis, Virilon
Roswell Park Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
12/26
12/27
NCT05149131: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

Completed
N/A
960
Canada
ADT (Eligard®*) with or without treatment intensification
Bayer
Metastatic Castration-sensitive Prostate Cancer
08/22
08/22
RCT-PHART2, NCT04239599: Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer

Active, not recruiting
N/A
178
NA
Hypofractionated IMRT Radiation treatment, Eligard 22.5 mg (28.2 mg leuprolide acetate per syringe) [3-Month] for 18-36 months
Sunnybrook Health Sciences Centre, Sanofi
Prostate Cancer
12/23
12/23
READT, NCT03703778: Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia ( Asia Study)

Active, not recruiting
N/A
300
RoW
Androgen deprivation therapy - bilateral orchidectomy, Androgen deprivation therapy - GnRH agonist, Enantone, Eligard, Androgen deprivation therapy - GnRH antagonist, Degarelix
Chinese University of Hong Kong
Prostate Cancer
12/25
03/26
NCT02588404: The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Withdrawn
N/A
65
NA
LHRH therapy, Eligard, Lupron, Trelstar, and Zoladex
Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
01/30
01/30
Olomax (amlodipine/olmesartan/rosuvastatin) / Daewoong Pharma
NCT05660135: Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

Active, not recruiting
N/A
4000
RoW
Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Daewoong Pharmaceutical Co. LTD.
Hypertension, Dyslipidemias
11/24
06/25
NCT05184179: Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

Completed
N/A
5450
RoW
Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
Daewoong Pharmaceutical Co. LTD.
Hypertension, Dyslipidemia
08/22
08/22
BBT-401 / Bridge Biotherap
2020-003556-33: A Placebo-controlled Study of BBT-401-1S in Subjects with Moderate to Severe Ulcerative Colitis

Not yet recruiting
2
36
Europe
BBT-401-1S, BBT-401-1S, Capsule
Bridge Biotherapeutics, Inc., Bridge Biotherapeutics, Inc.
Moderate to severe ulcerative colitis., A chronic disorder characterized by inflammation of intestinal mucosa, primarily the colon, as well as the rectum., Diseases [C] - Digestive System Diseases [C06]
 
 
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
4
2862
RoW
Enavogliflozin, Dapagliflozin or Empagliflozin
Yonsei University
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
09/29
12/30
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting
4
200
RoW
enavogliflozin 0.3mg, enavogliflozin Placebo
Yonsei University
Nonobstructive Hypertrophic Cardiomyopathy
11/26
11/26
ENVY, NCT06782139: Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting
4
30
RoW
Enavogliflozin, Placebo
Korea University Anam Hospital, Daewoong Pharmaceutical Co. LTD.
Obesity and Type 2 Diabetes
12/25
12/25
ENAVO-TAVR, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis, Heart Failure
12/26
04/27
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
3
134
NA
DWP16001 0.3 mg
Daewoong Pharmaceutical Co. LTD.
T2DM (Type 2 Diabetes Mellitus)
09/25
09/25
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruiting
3
340
RoW
DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
02/24
09/24
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Recruiting
3
240
RoW
DWP16001 0.3mg, DWP16001 Placebo
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Acelex (polmacoxib) / CG Invites
NCT06590714: Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.

Recruiting
N/A
150
RoW
Experimental(Acelex cap m2mg), Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)
Eulji University Hospital, Dong-A ST Co., Ltd., Seoul National University Hospital
Rotator Cuff Tear
08/25
08/25
Olostar (rosuvastatin/olmesartan medoxomil) / Daewoong Pharma, Daiichi Sankyo
NCT05411887: Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

Active, not recruiting
N/A
2845
RoW
Rosuvastatin, Olmesartan Medoxomil
Daewoong Pharmaceutical Co. LTD.
Hyperlipidemias, Hypertension
03/25
06/25
Jeuveau (prabotulinumtoxinA-xvfs) / AEON Biopharma
NCT05840445: Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles

Completed
4
26
RoW
Onabotulinum toxin A, Botox, Prabotulinumtoxin A, Nabota
Instituto de Oftalmología Fundación Conde de Valenciana
Face, Skin Fold, Rejuvenation
01/21
01/21
NCT06903975: BoTox Into the Sternocleidomastoid Muscles (SCM)

Recruiting
4
30
US
prabotulinumtoxinA-xvfs, Jeuveau
Boston Medical Center, Evolus, Inc.
Neck Muscle Issue
03/26
03/26
NCT06354127: DWP450 for Treating Moderate to Severe Glabellar Lines

Completed
3
473
RoW
DWP450, Botox®
Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
11/20
01/21
EVOLUS-CLIN201, NCT05320393: Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Completed
2
154
US
PrabotulinumtoxinA-Xvfs, Jeuveau, OnabotulinumtoxinA, Botox Cosmetic
Evolus, Inc., ethica Clinical Research Inc.
Glabellar Frown Lines
05/23
05/23
NCT04871451: Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia

Completed
2
51
US
ABP-450, prabotulinumtoxinA
AEON Biopharma, Inc., PPD
Cervical Dystonia
07/23
07/23
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT04965311: Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Terminated
2
4
US
Botulinum Toxin Type A, AbobotulinumtoxinA, Botox, Botox Cosmetic, Botulinum A Toxin, Botulinum Neurotoxin Type A, Botulinum Toxin A, BTX-A, DaxibotulinumtoxinA, Dysport, EvabotulinumtoxinA, IncobotulinumtoxinA, OnabotulinumtoxinA, Onaclostox, Prabotulinumtoxin A, Xeomin
OHSU Knight Cancer Institute, Oregon Health and Science University
Pancreatic Carcinoma
07/24
07/24
NCT05016661: Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

Terminated
2
466
Canada, US, RoW
ABP-450, prabotulinumtoxinA
AEON Biopharma, Inc., PPD DEVELOPMENT, LP
Migraine
07/24
08/24
NCT04715048: Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Active, not recruiting
1
20
US
PrabotulinumtoxinA, Jeuveau, Onabotulinum toxin A, Botox
University of Southern California
Glabellar Frown Lines
05/25
06/25
NCT05129319: Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Completed
1
30
US
prabotulinumtoxinA, Jeuveau
Clinical Testing of Beverly Hills, Evolus, Inc.
Glabellar Frown Lines
06/23
06/23
NCT05807412: Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Completed
1
10
US
PrabotulinumtoxinA-Xvfs, Jeaveau, OnabotulinumtoxinA, Botox
Lupo Center for Aesthetic and General Dermatology, Evolus, Inc.
Rhytides
02/24
02/24
NCT06604832: Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Recruiting
1
20
US
PrabotulinumtoxinA-Xvfs, Jeuveau, IncobotulinumtoxinA, Xeomin, saline solution (placebo)
Kalpna Kay Durairaj, MD, FACS, Evolus, Inc.
Skin Aging, Skin Wrinkling
01/25
02/25
NCT05889026: The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity

Completed
N/A
16
RoW
Extracorporeal shock wave therapy, Botulinum toxin treatment
Korea University Guro Hospital, Daewoong Pharmaceutical Co. LTD.
Stroke, Hemiplegia, Spastic, Muscle Spasticity
09/21
09/21
JBDX, NCT05167864: Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Completed
N/A
143
US
Onabotulinumtoxina for Injection, Botox, Abobotulinumtoxina for Injection, Dysport, IncobotulinumtoxinA for Injection, Xeomin, PrabotulinumtoxinA for Injection, Jeuveau
University of Pennsylvania
Cosmetic Techniques
06/23
06/23
NCT05481931: Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Recruiting
N/A
750
Europe
prabotulinumtoxinA, Jeuveau, Nuceiva
Evolus, Inc., Avania
Glabellar Frown Lines
12/25
01/26
Novosis (bongros/BMP-2) / Daewoong Pharma
2008-000926-38: An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 3.57 mg implant versus the reference product Enantone Monats-Depot

Ongoing
3
40
Europe
Novosis Leuprorelin 3.57 Implant, Implant, Enantone(R) Monats-Depot
Novosis AG
Patients who have advanced carcinoma of the prostate suitable for hormonal manipulation
 
 
NCT07017634: Efficacy and Safety of NOVOSIS Putty for Interbody Lumbar Fusion Cases

Not yet recruiting
3
316
NA
Novosis Putty, Standard of Care
CGBio Inc., CGBio USA
Degenerative Disc Disease
01/28
01/31
NCT06715345: Efficacy and Safety of Novosis Putty for Degenerative Lumbar Disease

Active, not recruiting
N/A
48
RoW
Bone graft materials and rhBMP-2
CGBio Inc.
Degenerative Lumbar Diseases
06/24
12/25
tanfanercept (HL036) / Daewoong Pharma
ChiCTR2000039903: A Phase 3, Multicenter, Randomized, Double–Blinded and Placebo–Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects with Moderate and Severe Dry Eye

Recruiting
3
674
 
Local administration of HBM9036 (HL036) eye drops (0.25%) to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks ;Local administration of placebo to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks
Xiamen Eye Center Affiliated to Xiamen University; Harbour BioMed (Guangzhou) Co., Ltd., Fully self-funded
Dry Eye
 
 
NCT04633213: A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Recruiting
3
674
RoW
HBM9036 0.25% Ophthalmic Solution, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye
12/22
04/23
VELOS-4, NCT06400589: A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Suspended
3
750
US
tanfanercept, Vehicle
HanAll BioPharma Co., Ltd.
Dry Eye
08/25
08/25
batoclimab (IMVT-1401) / Roivant
2021-000249-42: Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG Studio di fase 3 per valutare l’efficacia e la sicurezza di Batoclimab come terapia di induzione e di mantenimento in partecipanti adulti affetti da miastenia grave generalizzata (gMG).

Ongoing
3
240
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Diseases [C] - Nervous System Diseases [C10]
 
 
MG, NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized Patients

Completed
3
132
RoW
HBM9161 Injection (680mg), Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
01/23
01/23
2022-002787-68: Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Studio di fase 3 per testare Batoclimab in partecipanti affetti da oftalmopatia tiroidea (TED) attiva

Not yet recruiting
3
100
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences, GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Diseases [C] - Eye Diseases [C11]
 
 
NCT05332210: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Recruiting
3
144
RoW
HBM9161 Injection (680mg)
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
09/23
12/23
ChiCTR2100050903: Multicenter, randomized, double-blind, placebo-controlled, phase 2/3 operational seamless, group sequential design study of the efficacy and safety of HBM9161 subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia Gravis
 
 
NCT05403541 / 2021-000249-42: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Active, not recruiting
3
240
Europe, Canada, Japan, US, RoW
Batoclimab 680 mg SC weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis
03/25
04/25
ChiCTR2200059452: A long-term open-label extension study to evaluate the safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 680 mg was administered once a week (QW) ;HBM9161 340mg was administered 6 times per cycle for two cycles
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia gravis
 
 
NCT05517421 / 2022-002787-68: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Active, not recruiting
3
100
Europe, Canada, Japan, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05524571 / 2022-002788-30: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Recruiting
3
100
Europe, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05517447 / 2022-002839-66: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Recruiting
3
180
Europe, US, RoW
Observational cohort study, Batoclimab, IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
08/26
08/26
NCT04428255: A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Recruiting
2/3
36
RoW
HBM9161 Dose A, HBM9161 Dose B, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Primary Immune Thrombocytopenic Purpura
07/21
03/23
NCT05015127: A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Recruiting
2/3
36
RoW
HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7
Harbour BioMed (Guangzhou) Co. Ltd.
Thyroid Ophthalmopathy
10/22
12/22
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients, ChiCTR2000033560: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
HBM9161 dose 1 ;HBM9161 dose 2 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Myasthenia Gravis
 
 
ChiCTR2100050401: A randomized, double-blind, placebo-controlled, phase 2/3 operational seamless design clinical study to evaluate the efficacy and safety of subcutaneous injection of HBM9161 in Chinese patients with active, moderate-to-severe thyroid eye disease (TED)

Not yet recruiting
2
30
 
HBM9161 Once a week ;HBM9161 1 time / week + 2 times / week ;Placebo
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Harbour BioMed(Suzhou) Co., Ltd., Harbour BioMed(Suzhou) Co., Ltd.
Thyroid Eye Disease (TED)
 
 
2022-002894-27: Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones.

Not yet recruiting
2
45
Europe
batoclimab, IMVT-1401, Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves, disease, An immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism)., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05907668 / 2022-002894-27: A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Active, not recruiting
2
35
Europe
IMVT-1401 (batoclimab), IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves Disease
07/25
07/25
NCT05581199 / 2022-002718-17: To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Active, not recruiting
2
277
Europe, Canada, US, RoW
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Placebo
Immunovant Sciences GmbH, Immunovant Sciences, GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
01/26
01/27
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China.

Recruiting
1
18
 
HBM9161
The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Neuromyelitis optica spectrum disorders
 
 
Eligard (leuprolide acetate) / Tolmar, Sanofi
2006-001909-28: Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de la recidiva bioquímica del cáncer de próstata tratado con radioterapia.

Ongoing
4
180
Europe
BUSERELINA, GOSERELINA, LEUPRORELINA, TRIPTORELINA, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL
Grupo GICOR
Cáncer de próstata tratado con radioterapia y que presenta recidiva bioquímica.
 
 
2011-004749-41: The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatment

Ongoing
4
400
Europe
Casodex 50mg, Eligard 22.5 mg, N/A, Casodex 50mg, Eligard 22.5 mg, Casodex 50mg, Eligard 22.5 mg
TweeSteden hospital, Astella's pharma
Localized prostate cancer
 
 
NEST, NCT06926933: Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

Recruiting
4
50
RoW
Eligard® 45 mg
HanAll BioPharma Co., Ltd.
CPP
04/26
10/27
NCT02811471: Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Recruiting
3
5
US
Leuprolide
Nemours Children's Clinic, Tolmar Inc.
Central Precocious Puberty
07/17
07/18
2019-003177-26: Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Vergelijken van gerichte radiotherapie met en zonder kortdurende hormonale behandeling (6 maanden)

Not yet recruiting
3
280
Europe
Eligard, Powder for suspension for injection, Eligard, Leuproline acetaat 1x 45 mg sc
UMCG, UMCG
Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases Patiënten met biochemisch recidief na primaire behandeling van prostaatkanker met ≤4 metastasen, Metastatic prostate cancer Uitgezaaide prostaat kanker, Diseases [C] - Cancer [C04]
 
 
2022-000066-18: Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen. Onderzoek naar metastase gerichte therapie al dan niet in combinatie met hormoontherapie bij patiënten met een herval van prostaatkanker na initiële behandeling en maximum 5 metastasen.

Not yet recruiting
3
873
Europe
Implant in pre-filled syringe, Powder and solvent for solution for injection, Powder and solvent for suspension for injection, Capsule, soft, Zoladex 3,6 mg implant, Depo-Eligard 7,5 mg implant, Decapeptyl Sustained Release 11,25 mg, Zoladex Long Acting, 10,8 mg, implantaat, Depo-Eligard 45 mg implant, Depo-Eligard 22,5 mg implant, Decapeptyl Sustained Release 3,75 mg, Decapeptyl Sustained Release 22,5 mg, Xtandi 40 mg soft capsules
Universitaire Ziekenhuizen Leuven, Universitaire Ziekenhuizen Leuven
Oligorecurrent hormone-sensitive prostate cancer patients, Recurrent hormone-sensitive prostate cancer patients with maximum 5 metastasis, Diseases [C] - Cancer [C04]
 
 
2021-006975-41: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: un ensayo fase III aleatorizado, controlado, multicéntrico

Not yet recruiting
3
534
Europe
triptorelina equivalente, triptorelina (pamoato), leuprorelina, goserelina, Powder and solvent for prolonged-release suspension for injection, Powder and solvent for solution for injection, Powder and solution for solution for injection, Powder and solvent for suspension for injection in pre-filled syringe, Powder and solvent for solution for injection in pre-filled syringe, Implant in pre-filled syringe, Decapeptyl semestral, Decapeptyl trimestral, Eligard mensual, Eligard semestral, Eligard trimestral, Procrin Mensual, Procrin Semestral, Procrin Trimestral, Zoladex
GICOR, GICOR
Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía, prostate cancer cáncer de próstata, Diseases [C] - Cancer [C04]
 
 
ADOPT, NCT04302454: Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

Active, not recruiting
3
280
Europe
Radiotherapy, MDRT, Metastase-directed radiotherapy, SBRT, Stereotactic body radiotherapy, Leuprorelin, Eligard
University Medical Center Groningen, Dutch Cancer Society
Prostate Cancer
10/27
12/27
EMBARK, NCT02319837 / 2014-001634-28: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer

Active, not recruiting
3
1068
Europe, Canada, US, RoW
Enzalutamide, MDV3100, Xtandi, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label, Eligard, Leuprolide Acetate, Leuprorelin, Lupron
Pfizer, Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
01/23
09/26
PCS-XII, NCT06855589: Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

Not yet recruiting
3
400
Canada
6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
Charles LeMoyne Hospital
Prostate Cancer (Adenocarcinoma)
03/33
03/34
OVELIA, NCT04906395: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Active, not recruiting
3
250
Canada, US, RoW
TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
Tolmar Inc.
Breast Cancer
04/26
04/26
AFU-GETUG-20, NCT01442246 / 2010-022037-29: Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Active, not recruiting
3
700
Europe
Leuprorelin Acetate, Eligard®
UNICANCER, Astellas Pharma Inc
Metastases
09/27
09/27
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
ERADICATE, NCT04484818: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The Study

Active, not recruiting
3
27
US
Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
12/25
05/28
NCT05645536: Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Enrolling by invitation
3
250
US, RoW
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Tolmar Inc.
Breast Cancer
06/28
06/28
INDICATE, NCT04423211: Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
3
804
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Degarelix, FE200486, Firmagon, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Proton Therapy, IMPT, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline, Volume Modulated Arc Therapy, VMAT, Volumetric Modulated Arc Therapy (procedure)
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
12/32
12/32
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
GROUQ-PCS 9, NCT02685397: Management of Castration-Resistant Prostate Cancer with Oligometastases

Active, not recruiting
2/3
102
Canada
Leuprolide Acetate, Eligard, Lupron, Goserelin Acetate, ZOLADEX, Triptorelin, Trelstar, Enzalutamide, Xtandi, Stereotactic Body Radiation Therapy, SBRT
Sir Mortimer B. Davis - Jewish General Hospital
Castration-resistant Prostate Cancer Patients with Oligometastases
04/27
08/41
NRG-GU002, NCT03070886: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Active, not recruiting
2/3
612
Canada, US
Bicalutamide, Casodex, Cassotide, Cosudex, ICI 176,334, ICI 176334, Utamide, Degarelix, ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide, Leuprorelin, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908
NRG Oncology, National Cancer Institute (NCI)
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
05/26
05/26
ACTRN12609000108213: The utility of 18F-fluro-deoxy-glucose (FDG) and 11C-choline (C) positron emission tomography (PET scan) for radiotheraupetic management of high risk prostate cancer patients

Not yet recruiting
2
30
 
Austin Health, National Health and Medical Research Council (NHMRC)
Prostate cancer
 
 
NCT00544830: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting
2
29
US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
City of Hope Medical Center, National Cancer Institute (NCI)
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
03/11
03/26
OLIGOPELVIS, NCT02274779: Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Active, not recruiting
2
70
Europe
ELIGARD, Leuproréline
Institut Cancerologie de l'Ouest, Astellas Pharma Inc
Prostate Cancer
07/18
07/26
2022-002431-53: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER DAROLUTAMIDE (ODM-201) CONCOMITANT A LA RADIOTHERAPIE CHEZ LES PATIENTS PRESENTANT UN CANCER DE LA PROSTATE A RISQUE INTERMEDIAIRE DEFAVORABLE : UNE ETUDE MULTICENTRIQUE RANDOMISEE NON-COMPARATIVE DE PHASE II

Ongoing
2
62
Europe
DAROLUTAMIDE, Dégarélix, Goséréline, Leuproréline, Triptoréline, RADIOTHERAPY, Tablet, Powder and solvent for solution for injection, Implant in pre-filled syringe, , NUBEQA, FIRMAGON, ZOLADEX, ELIGARD, ENANTONE, DECAPEPTYL, GONAPEPTYL, RADIOTHERAPY
Institut Bergonié, Bayer Healthcare SAS
Prostate cancer Cancer de la prostate, Intermediate unfavorable risk prostate cancer Cancer de la prostate à risque intermédiaire défavorable, Diseases [C] - Cancer [C04]
 
 
2022-002571-11: EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer.

Ongoing
2
20
Europe
Powder and solution for solution for injection, Eligard 22.5mg
Institut Mutualiste Montsouris, Institut Mutualiste Montsouris
Intermediate risk localized prostate cancer Cancer localisé de la prostate à risque intermédiaire, Intermediate risk prostate cancer, Diseases [C] - Cancer [C04]
 
 
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
NCT02903368: Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Completed
2
118
US
Apalutamide, JNJ-56021927, ARN-509, Leuprolide, Lupron, Eligard, Prednisone, Deltasone, Abiraterone Acetate, Zytiga
Dana-Farber Cancer Institute, Janssen Scientific Affairs, LLC
Prostate Cancer
04/22
07/24
PROMPT, NCT04249154: Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Recruiting
2
77
Canada
Eligard, Radiation
McGill University Health Centre/Research Institute of the McGill University Health Centre, Tolmar Inc.
Prostate Cancer
12/26
12/27
NCT04734730: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting
2
70
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Talazoparib, BMN 673, BMN-673
City of Hope Medical Center, National Cancer Institute (NCI)
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
08/27
08/27
SHARP, NCT03361735: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting
2
25
US
Leuprolide Acetate, 377526, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate, 74381-53-6, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Goserelin Acetate, 606864, 65807-02-5, D-Ser(bu(t))(6)azgly(10)-LHRH Acetate, ZDX, Zoladex, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Radium Ra 223 Dichloride, 444811-40-9, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM CHLORIDE RA-223, Radium-223 Dichloride, Xofigo, Laboratory Biomarker Analysis, Degarelix, 214766-78-6, FE200486, Firmagon
City of Hope Medical Center
Prostate Adenocarcinoma
02/26
02/26
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
09/25
12/25
SATURN, NCT03902951: Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Active, not recruiting
2
28
US
Abiraterone Acetate, CB7630, Zytiga, Apalutamide, ARN 509, ARN-509, ARN509, JNJ 56021927, JNJ-56021927, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Jonsson Comprehensive Cancer Center, Janssen Inc.
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
01/26
01/27
NRG-GY033, NCT06169124: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Active, not recruiting
2
37
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Exemestane, Aromasin, FCE-24304, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI), NRG Oncology
Adult Ovarian Granulosa Cell Tumor
05/27
05/27
NCT06330805: Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Recruiting
2
70
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Contrast Agent, Contrast, Contrast Drugs, contrast material, Contrast Medium, Leuprolide, Leuprorelin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Physical Performance Testing, Physical Fitness Testing, Physical Function Testing, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385
Ohio State University Comprehensive Cancer Center, Pfizer, Myovant Sciences GmbH, Sumitomo Pharmaceuticals America
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
12/27
12/27
NCI-2018-01856, NCT01786265: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Active, not recruiting
2
310
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Flutamide, 4''-Nitro-3''-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
M.D. Anderson Cancer Center
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
02/27
02/27
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Recruiting
2
180
US
Placebo, Eligard 22.5Mg Suspension for Injection
Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
08/26
08/26
NCT07027124: Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Not yet recruiting
2
40
US
Darolutamide, Nubeqa, Pembrolizumab, Keytruda, Lupron, Leuprolide
Icahn School of Medicine at Mount Sinai, Merck Sharp & Dohme LLC, Bayer
Prostate Cancer, High-risk Prostate Cancer
12/26
05/31
RATIONAL-PCS, NCT06654336: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Not yet recruiting
2
162
Canada
Recurrence-directed therapy (RDT), ELIGARD 22.5mg
Ontario Clinical Oncology Group (OCOG), Ontario Clinical Oncology Group (OCOG) - McMaster University, TOLMAR PHARMACEUTIQUES CANADA, INC.
Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer
04/31
06/31
NCT06922318: The COSMYC Trial (COmbined Suppression of MYC)

Not yet recruiting
2
50
US
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex, Trelstar, Eligard, Lupron, Degarelix, Relugolix
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Zenith Epigenetics, National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
08/31
08/31
APEX, NCT06059118: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
50
US
DFMO, eflornithine, difluoromethylornithine, testosterone cypionate, DEPO-Testosterone Injection, Luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex, Trelstar, Eligard, Lupron, Degarelix, Relugolix, Enzalutamide, Xtandi
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Panbela Therapeutics, Prostate Cancer Foundation, United States Department of Defense
Prostate Cancer
01/26
11/29
NCT05669664: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recruiting
2
21
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
04/27
04/27
NCT05617885: Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Active, not recruiting
1/2
9
US
Darolutamide, Nubeqa, Abemaciclib, Verzenio, GNRH-A Leuprolide Acetate, Eligard, Lupron Depot, Lupron Depot-Ped, GNRH-A Goserelin, Zoladex, Degarelix, Firmagon
Praful Ravi, MB BCHir, MRCP, Eli Lilly and Company, Bayer
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
07/25
06/26
NCT06305598: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1
14
US
Biopsy, BIOPSY_TYPE, Bx, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Survey Administration, Testosterone Cypionate, depAndro, Depo-Testosterone, Depotest, Depovirin, Pertestis, Virilon
Roswell Park Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
12/26
12/27
NCT05149131: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

Completed
N/A
960
Canada
ADT (Eligard®*) with or without treatment intensification
Bayer
Metastatic Castration-sensitive Prostate Cancer
08/22
08/22
RCT-PHART2, NCT04239599: Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer

Active, not recruiting
N/A
178
NA
Hypofractionated IMRT Radiation treatment, Eligard 22.5 mg (28.2 mg leuprolide acetate per syringe) [3-Month] for 18-36 months
Sunnybrook Health Sciences Centre, Sanofi
Prostate Cancer
12/23
12/23
READT, NCT03703778: Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia ( Asia Study)

Active, not recruiting
N/A
300
RoW
Androgen deprivation therapy - bilateral orchidectomy, Androgen deprivation therapy - GnRH agonist, Enantone, Eligard, Androgen deprivation therapy - GnRH antagonist, Degarelix
Chinese University of Hong Kong
Prostate Cancer
12/25
03/26
NCT02588404: The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Withdrawn
N/A
65
NA
LHRH therapy, Eligard, Lupron, Trelstar, and Zoladex
Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
01/30
01/30
Olomax (amlodipine/olmesartan/rosuvastatin) / Daewoong Pharma
NCT05660135: Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

Active, not recruiting
N/A
4000
RoW
Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Daewoong Pharmaceutical Co. LTD.
Hypertension, Dyslipidemias
11/24
06/25
NCT05184179: Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

Completed
N/A
5450
RoW
Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
Daewoong Pharmaceutical Co. LTD.
Hypertension, Dyslipidemia
08/22
08/22
BBT-401 / Bridge Biotherap
2020-003556-33: A Placebo-controlled Study of BBT-401-1S in Subjects with Moderate to Severe Ulcerative Colitis

Not yet recruiting
2
36
Europe
BBT-401-1S, BBT-401-1S, Capsule
Bridge Biotherapeutics, Inc., Bridge Biotherapeutics, Inc.
Moderate to severe ulcerative colitis., A chronic disorder characterized by inflammation of intestinal mucosa, primarily the colon, as well as the rectum., Diseases [C] - Digestive System Diseases [C06]
 
 
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
4
2862
RoW
Enavogliflozin, Dapagliflozin or Empagliflozin
Yonsei University
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
09/29
12/30
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting
4
200
RoW
enavogliflozin 0.3mg, enavogliflozin Placebo
Yonsei University
Nonobstructive Hypertrophic Cardiomyopathy
11/26
11/26
ENVY, NCT06782139: Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting
4
30
RoW
Enavogliflozin, Placebo
Korea University Anam Hospital, Daewoong Pharmaceutical Co. LTD.
Obesity and Type 2 Diabetes
12/25
12/25
ENAVO-TAVR, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis, Heart Failure
12/26
04/27
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
3
134
NA
DWP16001 0.3 mg
Daewoong Pharmaceutical Co. LTD.
T2DM (Type 2 Diabetes Mellitus)
09/25
09/25
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruiting
3
340
RoW
DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
02/24
09/24
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Recruiting
3
240
RoW
DWP16001 0.3mg, DWP16001 Placebo
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
09/24
09/24
 

Download Options